Naltrexone/Bupropion Approved as Mysimba for Obesity in EU Naltrexone/Bupropion Approved as Mysimba for Obesity in EU
Naltrexone HCl/bupropion HCl prolonged release joins liraglutide as the second drug to be approved for obesity this week in the European Union. International Approvals
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Bupropion | Diabetes | Eating Disorders & Weight Management | Endocrinology | Obesity | Primary Care | Victoza | Wellbutrin